

Camurus AB Ideon Science Park SE-223 70 Lund, Sweden www.camurus.com Phone: +46 46 286 57 30

Press release

Camurus to host a Capital Markets Day 14 December 2016

Lund, Sweden — Camurus AB (Nasdaq Stockholm; CAMX) today announces that they will host a Capital Markets Day on 14th December in Stockholm.

Presentations will be made by President and CEO Fredrik Tiberg and parts of Camurus management team and Behshad Sheldon, CEO Braeburn Pharmaceuticals.

Time: Wednesday 14 December, 1.30pm – 5.00pm CET Venue: IVA Conference Center, Grev Turegatan 16, Stockholm Invitation for: Institutional investors, analysts and media

Registration for investors, analysts and journalists

To participate, please register no later than 9 December at; CMD@camurus.com

A detailed program will be posted in mid-November on Camurus website <u>www.camurus.com</u>.

For more information please contact:

ir@camurus.com

About Camurus

Camurus is a Swedish research-based pharmaceutical company committed to developing and commercialising innovative and differentiated medicines for the treatment of severe and chronic conditions. New drug products with best-in-class potential are conceived based on the proprietary FluidCrystal® drug delivery technologies and an extensive R&D expertise. Camurus' clinical pipeline includes products for treatment of cancer, endocrine diseases, pain and addiction, developed inhouse and in collaboration with international pharmaceutical companies. The company's shares are listed on Nasdaq Stockholm under the ticker "CAMX". For more information, visit <u>www.camurus.com</u>.

The information was submitted for publication at 07.00 a.m. CET on 1 November 2016.